ABSI (Absci Bio) צמיחה צפויה ברווח נקי למניה השנה

Absci is scaling antibody creation via AI, replacing routine tests with neural networks. The year-over-year percentage change in EPS, featured on the GURU.Markets terminal linear chart, demonstrates profit dynamics where 5.20 shows the value of this parameter. The company is optimizing expenses by utilizing external computing and logistics, while unique biodata sets create a sustainable market moat.

To identify the sector's fundamental leaders, analysts utilize year-over-year net income per share dynamics, which measure business efficiency rates. This calculation reflects the ability of Absci (ABSI) to monetize its unique AI protein design toolkit through significant pricing power, allowing for the tracking of profit sustainability via the relative EPS YoY trend.